InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
NeuroPace $74.75 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
BioVersys CHF 80 million IPO and concurrent private placement
We advised AMR Action Fund on its investment in BioVersys
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065
GH Research $150 million follow-on offering
We advised GH Research on the offering of shares
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Outlook Therapeutics $20.4 million warrant liability transaction
Certain holders agreed to exercise Outlook Therapeutics warrants at a reduced exercise price while receiving new warrants
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction